Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Status
Status :
Completed
Type of study
RWE
Min. Age
18
Years old
Max. Age
-
Gender
All
Brief summary
Encorafenib in combination with Cetuximab in BRAFV600E–Mutated Metastatic Colorectal Cancer: A European pooled analysis of observational studies
Therapeutic area :
Oncology
Disease :
BRAFV600E - mutant metastatic colorectal cancer
Study medication :
Encorafenib (BRAFTOVI®)
Phase :
RWE
Start Date :
01 August 2024
End Date / Planned study Completion Date :
31 December 2026
Sponsor(s) or Co-Sponsor(s) :
- Association des gastro entéroloques oncologues (AGEO)
- Dutch colorectal cancer group (DCCG)
- FONDAZIONE GONO - Gruppo Oncologico Del Nord Ovest
- Grupo de tratamiento de los tumores digestivos Spanish cooperative group for the treatment of digestive tumours (TTD)
- Laboratoires Pierre Fabre
Countries :
Austria
France
Germany
Italy
Netherlands
Spain
Switzerland
Contact Us
Need more information, click on the button to have access to the contact form.
Access to Lay Protocol Synopsis
A summary of the protocol, written in simple terms and describing the objectives of the study, is provided for your information.
Send by email